Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Cancer Research UK Signs Deal With Centella Therapeutics, Inc. to Launch Clinical Development of Radiotherapy-Enhancing Drug

May 25, 2011 By Bio-Medicine.Org

PALO ALTO, Calif. and LONDON, May 25, 2011 /PRNewswire/ —
Cancer Research UK and Cancer Research Technology – the charity’s
development and commercialisation arm – have partnered with
Centella Therapeutics, Inc. of Palo Alto, California, to develop,
manufacture and trial a promising new drug, CEN-209 in cancer
patients with solid tumours.  

CEN-209*, discovered at the Auckland Cancer Society Research
Centre and exclusively licensed to Centella from Auckland
Uniservices Ltd. of New Zealand, is designed to provide benefit
when used together with radiotherapy and chemotherapy to treat
solid tumours. CEN-209 is the seventh drug candidate to enter
Cancer Research UK’s Clinical Development Partnerships (CDP)
scheme.  (See related press release: Centella
Therapeutics Licenses Novel New Drug Designed to Enhance the
Effectiveness of Cancer Treatment, May 23, 2011).

CEN-209 has the potential to destroy the areas of tumours which
are low in oxygen – or hypoxic. Tumour cells become hypoxic
because the blood vessels supplying them with nutrients and oxygen
are often weak, twisted and ineffective due to the rapid growth of
the tumour.  

Cancer cells that are hypoxic are more resistant to chemotherapy
and radiotherapy and often survive such treatment. By destroying
the hypoxic part of tumours with CEN-209 in parallel to
chemotherapy and radiotherapy, it is hoped that this combination
treatment will be more effective.

CDP is a joint initiative between Cancer Research UK’s Drug
Development Office and Cancer Research Technology, to develop
promising anti-cancer agents from companies that are not able to
take them through early phase clinical trials themselves. The CDP
scheme allows companies to retain the background rights to their
programmes while enabling Cancer Research UK to take on early
development work to assess if there is a potential benefit to
ca

‘/>”/>

SOURCE

Related Articles Read More >

A photo of nitinol, a nickel-titanium alloy used for medical devices such as stents, heart valves, catheters and orthopedics.
What is nitinol and where is it used?
An image of Abbott's Infinity deep brain stimulation (DBS) implants and leads.
How Abbott developed the first-of-its-kind Infinity DBS system
Axoft Fleuron brain-computer interface BCI probe
Axoft makes Fleuron BCI material available for purchase, inks license deal with Stanford
An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]
The top nitinol cardiac medtech news of 2025 (so far)
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe